San Diego-dependent Viking Therapeutics marked by itself as a serious competitor in the weight loss drug market place in February following revealing promising information from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection As well as in March th